China National Pharmaceutical Group Corporation: Wholly-owned subsidiary receives drug supplementary application approval notice.

Guoyao Modern announced that its wholly-owned subsidiary, Guoyao Group Rongsheng Pharmaceutical Co., Ltd., has received the "Drug Supplement Application Approval Notice" issued by the National Medical Products Administration, approving the increase in specification of sodium bicarbonate injection and passing the generic drug quality and efficacy consistency evaluation. Sodium bicarbonate injection is an anti-acid drug, indicated for the treatment of metabolic acidosis, prevention of uric acid kidney stones, etc. The sales of sodium bicarbonate injection in public medical institutions nationwide in 2024 is approximately 580 million yuan. Currently approved through consistency evaluation enterprises also include Hefei Yuanfengshun Medical Science and Technology Co., Ltd. Guoyao Rongsheng's cumulative R&D investment is approximately 2.7442 million yuan. This event will benefit the future market expansion and sales of the product, but will not have a significant impact on the current performance of the company.